The Cognitive Assessment Interview (CAI): Reliability and validity of a brief interview-based measure of cognition

Schizophrenia Bulletin

Volumn 39, Issue 3, 2013, Pages 583-591

  Ventura, Joseph ^a   Reise, Steven P ^b   Keefe, Richard S E ^c   Hurford, Irene M ^d,e   Wood, Rachel C ^a   Bilder, Robert M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

functional capacity; functional outcome; informant ratings; neurocognition; schizophrenia; symptoms

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; COGNITION; COGNITIVE ASSESSMENT INTERVIEW; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL STATUS; TEST RETEST RELIABILITY; VALIDITY; WORK CAPACITY;

ADULT; COGNITION DISORDERS; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MIDDLE AGED; PSYCHOMETRICS; PSYCHOTIC DISORDERS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84876560960     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbs001     Document Type: Article

References (39)

1. Burke L, Stifano T, Dawish S. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Rockville, MD: U.S. Department of Health and Human Services Food and Drug Administration; 2006.
2. Keefe RS, Poe M, Walker TM, Kang JW, Harvey PD. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am J Psychiatry. 2006;163:426-432. (Pubitemid 44469384)
3. Ventura J, Reise SP, Keefe RSE, et al. The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition. Schizophr Res. 2010;121:24-31.
4. Green MF, Nuechterlein KH, Kern RS, et al. Functional coprimary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry. 2008;165:221-228. (Pubitemid 351704522)
5. Ventura J, Cienfuegos A, Boxer O, Bilder R. Clinical global impression of cognition in schizophrenia (CGI-CogS): reliability and validity of a co-primary measure of cognition. Schizophr Res. 2008;106:59-69.
6. Reise SP, Ventura J, Keefe RSE, et al. Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia. Psychol Assess. 2011;23:245-261.
7. Green MF, Schooler NR, Kern RS, et al. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry. 2011;168: 400-407.
8. Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV. UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull. 2001;27:235-245. (Pubitemid 33644299)
9. Velligan DI, Diamond P, Glahn DC, et al. The reliability and validity of the Test of Adaptive Behavior in Schizophrenia (TABS). Psychiatry Res. 2007;151:55-66. (Pubitemid 46634636)
10. Nuechterlein KH, Green MF. MATRICS Consensus Cognitive Battery. Los Angeles, CA: MATRICS Assessment, Inc.; 2006.
11. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry. 2006; 163:418-425. (Pubitemid 44469383)
12. Bowie CR, Leung WW, Reichenberg A, et al. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry. 2008;63:505-511. (Pubitemid 351220787)
13. Chia MY, Chan WY, Chua KY, et al. The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia. Psychiatry Res. 2010;178:33-38.
14. Jungwirth S, Fischer P, Weissgram S, Kirchmeyr W, Bauer P, Tragl KH. Subjective memory complaints and objective memory impairment in the Vienna Transdanube aging community. J Am Geriatr Soc. 2004;52:263-268. (Pubitemid 38233491)
15. Moritz S, Ferahli S, Naber D. Memory and attention performance in psychiatric patients: lack of correspondence between clinician-rated and patient-rated functioning with neuropsychological test results. J Int Neuropsychol Soc. 2004;10:623-633. (Pubitemid 39077202)
16. Prouteau A, Verdoux H, Briand C, et al. Self-assessed cognitive dysfunction and objective performance in outpatients with schizophrenia participating in a rehabilitation program. Schizophr Res. 2004;69:85-91. (Pubitemid 38625762)
17. Farias ST, Mungas D, Jagust W. Degree of discrepancy between self and other reported everyday functioning by cognitive status: dementia, mild cognitive impairment, and healthy elders. Int J Geriatr Psychiatry. 2005;20:827-834. (Pubitemid 41358673)
18. First MB, Gibbon M, Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. Patient Edition. New York, NY: Biometrics Research; 1996.
19. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J. Training and quality assurance with the Structured Clinical Interview for DSM-IV(SCID-I/P). Psychiatry Res. 1998;79:163-173. (Pubitemid 28308489)
20. Ventura J, Green MF, Shaner A, Liberman RP. Training and quality assurance on the Brief Psychiatric Rating Scale: the "drift busters". Int J Methods Psychiatr Res. 1993;3:221-226.
21. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203-213. (Pubitemid 351704520)
22. Patterson TL, Lacro J, McKibbon CL, Moscona S, Hughs T, Jeste DV. Medication management ability assessment: results from a performance-based measure in older outpatients with schizophrenia. J Clin Psychopharmacol. 2002;22:11-19. (Pubitemid 34101287)
23. Ventura J, Lukoff D, Nuechterlein KH, Liberman RP, Green MF, Shaner A. Brief Psychiatric Rating Scale (BPRS) expanded version: scales, anchor points, and administration manual. Int J Methods Psychiatr Res. 1993;3:227-243.
24. Ventura J, Nuechterlein KH, Subotnik KL, Gutkind D, Gilbert EA. Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Res. 2000;97:129-135. (Pubitemid 32126552)
25. Andreasen NC, Carpenter WT, Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441.
26. Goldstein MJ. Further data concerning the relation between premorbid adjustment and paranoid symptomatology. Schizophr Bull. 1978;4:236-241. (Pubitemid 8353427)
27. Strauss JS, Carpenter WT. The prediction of outcome in schizophrenia, I: characteristics of outcome. Arch Gen Psychiatry. 1972;27:739-746.
28. Strauss JS, Carpenter WT. Prediction of outcome in schizophrenia, III: five-year outcome and its predictors. Arch Gen Psychiatry. 1977;34:159-163. (Pubitemid 8025013)
29. Stip E, Caron J, Renaud S, Pampoulova T, Lecomte Y. Exploring cognitive complaints in schizophrenia: the subjective scale to investigate cognition in schizophrenia. Compr Psychiatry. 2003;44:331-340. (Pubitemid 36875468)
30. Levene JE, Lancee WJ, Seeman MV. The perceived family burden scale: measurement and validation. Schizophr Res. 1996;22:151-157. (Pubitemid 26394562)
31. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEngl J Med. 2005;353:1209-1223.
32. Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res. 2009;113:189-199.
33. Ventura J, Thames AD, Wood RC, Guzik LH, Hellemann GS. Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophr Res. 2010;121:1-14.
34. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31:5-19. (Pubitemid 41214353)
35. Harvey PD, Keefe RS, Patterson TL, Heaton RK, Bowie CR. Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. J Clin Exp Neuropsychol. 2009;31:462-471.
36. Keefe RSE, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res. 2011;125:161-168.
37. Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RSE. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res. 2011;127:188-194.
38. Medalia A, Thysen J. Insight into neurocognitive dysfunction in schizophrenia. Schizophr Bull. 2008;34:1221-1230.
39. Medalia A, Thysen J, Freilich B. Do people with schizophrenia who have objective cognitive impairment identify cognitive deficits on a self report measure? Schizophr Res. 2008;105:156-164.